Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Idiopathic pulmonary fibrosis; Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms ARTEMIS-PH
- Sponsors Gilead Sciences
- 19 Sep 2014 New trial record